Market Place
Sourcing Support
Dogwood Therapeutics Announces Q3 2024 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
Dogwood Therapeutics to Report Q3 2024 Results on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
Dogwood Therapeutic Regain Compliance with Nasdaq Minimum Bid Price
30 Oct 2024 //
GLOBENEWSWIRE
Virios And Wex Announce Merger To Form Dogwood Therapeutics
07 Oct 2024 //
GLOBENEWSWIRE
Virios Therapeutics Announces Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Virios Therapeutics To Report Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
Virios Completes Enrollment In IMC-2 Phase 2 Long-COVID Study
23 Jul 2024 //
GLOBENEWSWIRE
Virios Closes $1.7M Offering To Prep IMC-2 Long COVID Study
22 May 2024 //
GLOBENEWSWIRE
Virios Prices $1.7M Offering For Long-COVID Phase 2b Prep
19 May 2024 //
GLOBENEWSWIRE
Virios Announces Proposed Offering For Long-COVID Phase 2b Prep
17 May 2024 //
GLOBENEWSWIRE
Virios Therapeutics Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Virios Therapeutics Q1 2024 Results On May 9
02 May 2024 //
GLOBENEWSWIRE
Virios Announces Publication of International Patent for Treatment of Long-COVID
26 Mar 2024 //
GLOBENEWSWIRE
Virios Announces Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress
28 Feb 2024 //
GLOBENEWSWIRE
Virios Therapeutics Announces Plans to Advance Development of IMC-2
22 Jan 2024 //
GLOBENEWSWIRE
Virios Reaches Alignment with FDA on Requirements for Advancing Candidate IMC-2
02 Jan 2024 //
GLOBENEWSWIRE
Virios Therapeutics Announce Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Virios Therapeutics to Report Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Virios to Present at the ThinkEquity Conference on Thursday, October 19, 2023
12 Oct 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
18 Sep 2023 //
GLOBENEWSWIRE
Virios CEO Greg Duncan to Present at the SHARE Series Investor Event
12 Sep 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
14 Aug 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Plans to Advance IMC-1 to Phase 3 Development
09 Aug 2023 //
GLOBENEWSWIRE
Virios Therapeutics to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Virios Announces Data Demonstrating Improvement in Multiple Long-COVID Symptoms
17 Jul 2023 //
GLOBENEWSWIRE
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
25 May 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Submission of Final Toxicology Results Ph3 Program
15 May 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Virios Therapeutics to Report 1Q 2023 FYR on Thursday, May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
Virios Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program
24 Apr 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Fourth Quarter & Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Virios to Report Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Virios Announces Data of Valacyclovir and Celecoxib, Projected in June 2023
13 Feb 2023 //
GLOBENEWSWIRE
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023
05 Jan 2023 //
GLOBENEWSWIRE
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
29 Nov 2022 //
BUSINESSWIRE
Virios Therapeutics Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Virios Therapeutics, Inc. Announces Closing of Public Offering
22 Sep 2022 //
BUSINESSWIRE
Short Volatility Alert: Virios Therapeutics, Inc.
21 Sep 2022 //
BENZINGA
Blaming Covid for data issues, antiviral biotech reports PIIb fibromyalgia fail
20 Sep 2022 //
ENDPTS
Virios Therapeutics, Inc. Announces Pricing of Public Offering
19 Sep 2022 //
BUSINESSWIRE
Virios Therapeutics, Inc. Announces Proposed Public Offering
19 Sep 2022 //
PRESS RELEASE
Virios doses first subject in long Covid antiviral trial
16 Aug 2022 //
CLINICALTRIALSARENA
Virio Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
15 Aug 2022 //
BUSINESSWIRE
Virios Therapeutics Announces Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Virios Therapeutics to Report Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Virios` Promising Fibromyalgia Treatment Candidate Expects Sep`22 PhIIb Results
19 Jul 2022 //
STREETINSIDER
Virios` Study Featured in Peer-Reviewed Journal on HSV-1 Infection
01 Jun 2022 //
BUSINESSWIRE
Virios Therapeutics Announces First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Virios Completes Enrollment in PIIb “FORTRESS” Trial for Fibromyalgia
28 Apr 2022 //
BUSINESSWIRE
U.S. FDA Approves FoundationOne CDx as a Companion Diagnostic for EGFR Tx
17 Mar 2022 //
BUSINESSWIRE
Virios Tx says Q4 and FY 2021 Financial Results
16 Mar 2022 //
BUSINESSWIRE
Virios Tx to Report Q4 and Full Year 2021 Financial Results on March 17
10 Mar 2022 //
BUSINESSWIRE
Virios Therapeutics to Present at the 34th Annual Roth Conference
08 Mar 2022 //
BUSINESSWIRE
Virios and BHC partner to analyse antiviral combination for long Covid
01 Mar 2022 //
PHARMACEUTICAL-TECHNOLOGY
Virios Tx Announces Collaboration in Combination Antiviral Therapy
28 Feb 2022 //
BUSINESSWIRE
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
08 Sep 2021 //
BUSINESSWIRE
Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination
08 Sep 2021 //
BIOSPACE
Virios Therapeutics Announces New Social Media Profiles
19 Aug 2021 //
BUSINESSWIRE
